Alpha 2.0
Login Register
» Authors » Ayman Kharaba

Ayman Kharaba

Explore the profile of Ayman Kharaba including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 1336
Followers 0
Related Specialties
General Medicine
Pharmacology
Infectious Diseases
Top 10 Co-Authors
Yaseen M Arabi
Ahmed Mady
Jesna Jose
Fahad Al-Hameed
Awad Al-Omari
Yasser Mandourah
Abdullah AlMotairi
Abdulaziz Al-Dawood
Frederick G Hayden
Hanan H Balkhy
Published In
Trials
J Epidemiol Glob Health
J Infect Public Health
Influenza Other Respir Viruses
BMC Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Statistical analysis plan for the replacing protein via enteral nutrition in a stepwise approach in critically ill patients (REPLENISH) randomized clinical trial
Arabi Y, Al-Dorzi H, Aldibaasi O, Sadat M, Jose J, Muharib D, et al.
Trials . 2024 May; 25(1):296. PMID: 38698442
Background: The optimal amount and timing of protein intake in critically ill patients are unknown. REPLENISH (Replacing Protein via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial...
2.
Replacing protein via enteral nutrition in a stepwise approach in critically ill patients: the REPLENISH randomized clinical trial protocol
Arabi Y, Al-Dorzi H, Sadat M, Muharib D, Algethamy H, Al-Hameed F, et al.
Trials . 2023 Jul; 24(1):485. PMID: 37518058
Background: Protein intake is recommended in critically ill patients to mitigate the negative effects of critical illness-induced catabolism and muscle wasting. However, the optimal dose of enteral protein remains unknown....
3.
Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
Elhazmi A, Rabie A, Al-Omari A, Mufti H, Sallam H, Alshahrani M, et al.
J Clin Med . 2023 Mar; 12(6). PMID: 36983304
Background: Tocilizumab is a monoclonal antibody proposed to manage cytokine release syndrome (CRS) associated with severe COVID-19. Previously published reports have shown that tocilizumab may improve the clinical outcomes of...
4.
Detection of Carbapenem-resistance in CRE by Comparative Assessment of RAPIDEC CARBA NP and Xpert™Carba-R Assay
Eltahlawi R, Jiman-Fatani A, Gad N, Ahmed S, Al-Rabia M, Zakai S, et al.
Infect Drug Resist . 2023 Mar; 16:1123-1131. PMID: 36855392
Introduction: Carbapenem-resistant (CRE) infections resist nearly most available antimicrobials, resulting in poor clinical outcomes. Saudi Arabia has a relatively high CRE prevalence. This study aims to evaluate the sensitivity of...
5.
Long-term outcomes of patients with COVID-19 treated with helmet noninvasive ventilation or usual respiratory support: follow-up study of the Helmet-COVID randomized clinical trial
Arabi Y, Al-Dorzi H, Aldekhyl S, Al Qahtani S, Abdukahil S, Al Qasim E, et al.
Intensive Care Med . 2023 Feb; 49(3):302-312. PMID: 36820878
Purpose: To evaluate whether helmet noninvasive ventilation compared to usual respiratory support reduces 180-day mortality and improves health-related quality of life (HRQoL) in patients with acute hypoxemic respiratory failure due...
6.
Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial
Arabi Y, Aldekhyl S, Al Qahtani S, Al-Dorzi H, Abdukahil S, Al Harbi M, et al.
JAMA . 2022 Sep; 328(11):1063-1072. PMID: 36125473
Importance: Helmet noninvasive ventilation has been used in patients with COVID-19 with the premise that helmet interface is more effective than mask interface in delivering prolonged treatments with high positive...
7.
Machine learning decision tree algorithm role for predicting mortality in critically ill adult COVID-19 patients admitted to the ICU
Elhazmi A, Al-Omari A, Sallam H, Mufti H, Rabie A, Alshahrani M, et al.
J Infect Public Health . 2022 Jun; 15(7):826-834. PMID: 35759808
Background: Coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is currently a major cause of intensive care unit (ICU) admissions globally. The role...
8.
Predictors of survival from Acinetobacter in Saudi Arabian intensive care units: A prospective, one-year, six-city, ten-center cohort study
Kharaba A, Algethamy H, Hussein M, Al-Hameed F, AlGhamdi A, Hamdan A, et al.
J Infect Public Health . 2022 May; 15(6):677-684. PMID: 35623242
Background: Antibiotic-resistant Acinetobacter baumannii is a continuously-emerging worldwide health crisis, with mortality rates approaching 50% in intensive care unit (ICU) patients. The objective of this study was to evaluate regional,...
9.
Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial
Arabi Y, Aldekhyl S, Al Qahtani S, Al-Dorzi H, Abdukahil S, Jose J, et al.
Trials . 2022 Feb; 23(1):105. PMID: 35109898
Background: Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation has multiple advantages over other oxygen support...
10.
Incidence, outcomes, and predictors of Acinetobacter infection in Saudi Arabian critical care units
Kharaba A, Algethamy H, Hussein M, Al-Hameed F, AlGhamdi A, Hamdan A, et al.
J Crit Care . 2021 Sep; 66:109-116. PMID: 34508982
Background: Acinetobacter is an increasingly-problematic organism, especially in intensive care units (ICUs). In this study, we compared its incidence, outcomes, and predictors spanning eight ICUs in five geographically and climatologically-diverse...